Olsalazine
From Wikipedia, the free encyclopedia
 |
|
|
Olsalazine
|
|
| Systematic (IUPAC) name | |
| 5 - [(2Z) - 2 - (3 - carboxy - 4 - oxo - 1 - cyclohexa - 2,5 - dienylidene)hydrazinyl] - 2 - hydroxy - benzoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | A07 |
| PubChem | |
| Chemical data | |
| Formula | C14H10N2O6 |
| Mol. mass | 302.239g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 99% |
| Metabolism | ? |
| Half life | 0.9 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | ? |
Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. It is sold under the name Dipentum.
The chemical name is 3,3' -azobis (6-hydroxybenzoate)salicylic acid. It is sold as the disodium salt.
Like Balsalazide, Olsalazine is believed to deliver Mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is that active site of disease in ulcerative colitis.
Contents |
[edit] History
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.
[edit] Supply
The drug is supplied by UCB Pharma.
[edit] Other indications
The Australian biotech company Giaconda has developed a combination therapy for treat constipation-predominant Irritable Bowel Syndrome that uses olsalazine and the anti-gout drug colchicine.
[edit] External links
|
||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
